Oncology Radiopharmaceuticals Market

The oncology radiopharmaceuticals market is worth USD 10,080.0 million in 2025 and reaches USD 38,468.3 million by 2035, compounding at 14.33% a year. The figure is built bottom-up: roughly 4.2 million oncology radiopharmaceutical patient doses administered in 2025 across diagnostic PET and SPECT cancer tracers, lutetium-177 targeted therapies, alpha emitter therapies, and associated isotope supply and radiopharmacy services, at an average realised price of USD 2,400 per dose, triangulated against procedure volumes, product sales and isotope supply data. Doses grow 11.0% a year as targeted radioligand therapies expand into earlier lines and new cancers, while realised price per dose rises 3.0% a year as the mix shifts toward high value therapeutics. This study sits within our nuclear medicine and radiopharmaceuticals coverage and follows the published Douglas Insights methodology.

Why did big pharma suddenly buy into radiopharmaceuticals?

Because a new class of targeted cancer drugs proved it could work commercially at scale, and the largest drug companies decided they could not afford to be absent. Radiopharmaceuticals are drugs that carry a radioactive isotope; in the newest form, called radioligand therapy, a molecule designed to bind a protein found on cancer cells carries a radioactive payload that delivers radiation directly to tumours wherever they are in the body, sparing much of the surrounding healthy tissue. The same targeting molecule paired with a diagnostic isotope lets doctors image which patients’ tumours express the target before treating them, a pairing often called theranostics. Lutetium-177 therapies for neuroendocrine tumours and, more significantly, for advanced prostate cancer targeting the prostate specific membrane antigen, demonstrated clinical benefit and rapid commercial uptake, with the prostate therapy expanding into earlier treatment settings. That success triggered a wave of acquisitions, with several of the world’s largest pharmaceutical companies buying radiopharmaceutical developers and isotope capabilities for billions of dollars. The result is a pipeline aimed at many more cancers and an industry scaling rapidly. The exclusive chapter of this report ledgers isotope supply against projected demand, because isotope availability has become the binding constraint on growth.

What does this market include?

This study covers radiopharmaceuticals used to diagnose and treat cancer. Diagnostic PET and SPECT oncology tracers cover imaging agents used to detect, stage and select patients for treatment, including fluorodeoxyglucose, prostate specific membrane antigen tracers and other targeted imaging agents. Lutetium-177 targeted therapies cover radioligand therapies using the beta emitting isotope lutetium-177, including approved treatments for prostate cancer and neuroendocrine tumours and pipeline agents. Alpha emitter therapies cover treatments using alpha emitting isotopes such as radium-223 and actinium-225, which deliver more intense, shorter range radiation. Isotope supply and radiopharmacy services cover the production and supply of medical isotopes and the radiopharmacies that prepare and distribute doses. Non oncology nuclear medicine, such as cardiac and bone imaging outside cancer, imaging equipment such as PET and SPECT scanners, external beam radiotherapy, and brachytherapy sit outside the boundary. Value is measured at the realised price of doses and associated services.

Why is isotope supply the binding constraint?

Because radioactive isotopes decay, cannot be stockpiled, and are produced in a small number of facilities, so supply must grow in step with demand in real time. Lutetium-177 is produced in nuclear research reactors or through other routes, then purified, combined with the targeting molecule and shipped to hospitals within days before it decays. A limited number of reactors worldwide can produce it, several of them ageing, and unplanned outages have disrupted supply. Actinium-225, the most promising alpha emitter for many pipeline therapies, is even scarcer, historically produced in tiny quantities from legacy nuclear materials, and scaling its production requires new methods and facilities that are only now being built. Because every dose must be manufactured shortly before use, supply chains are complex, time critical and vulnerable to disruption. This is why pharmaceutical companies acquiring radiopharmaceutical developers have also invested heavily in isotope production and manufacturing capacity, and why isotope producers have become strategically important. For this market, it means that growth in doses depends on the pace at which isotope supply and dose manufacturing expand, not only on clinical demand.

What drives demand?

The first driver is proven clinical benefit. Radioligand therapies have shown meaningful benefit in advanced prostate cancer and neuroendocrine tumours, and label expansions into earlier treatment lines greatly enlarge the eligible patient population.

The second driver is the pipeline. Radiopharmaceuticals targeting other cancers, including breast, lung, colorectal and others, are in clinical development, and successful approvals would expand the market well beyond current indications.

The third driver is theranostic diagnostics. Each therapy requires diagnostic imaging to select patients and monitor response, so therapy growth drives demand for targeted diagnostic tracers.

The fourth driver is pharmaceutical industry investment. Large acquisitions and investments have brought substantial capital, development capability and commercial reach to the field.

What restrains the market?

Three restraints are modelled. Isotope supply is the most binding: limited reactor capacity, scarcity of actinium-225 and the time critical nature of production cap how many doses can be delivered and have caused shortages. Infrastructure and workforce are second: administering radiopharmaceutical therapy requires nuclear medicine facilities, trained physicians, radiation safety arrangements and in some cases patient isolation, and capacity in many hospitals is limited, creating bottlenecks in patient access. Clinical and reimbursement risk is third: pipeline agents may fail in trials, and high prices for therapies raise reimbursement questions in cost conscious health systems.

Which product categories carry the revenue?

Diagnostic PET and SPECT oncology tracers lead with 44% of 2025 revenue, USD 4,435.2 million, reflecting the large volume of cancer imaging procedures, including high value targeted tracers. Lutetium-177 targeted therapies hold 36%, USD 3,628.8 million, and grow fastest as approved therapies expand into earlier lines and new agents are approved, carrying very high value per dose. Alpha emitter therapies account for 12%, USD 1,209.6 million, a smaller share today but with substantial pipeline potential once actinium-225 supply scales. Isotope supply and radiopharmacy services contribute 8%, USD 806.4 million. Each category is modelled through 2035 by region.

Where are oncology radiopharmaceuticals used?

North America leads with 52% of 2025 revenue, USD 5,241.6 million, growing 13.7% a year, reflecting early approvals, high prices, extensive nuclear medicine infrastructure and rapid adoption of radioligand therapy. Europe holds 28%, USD 2,822.4 million, at 13.6%, with strong nuclear medicine traditions, particularly in Germany, and growing therapy use. Asia Pacific holds 15%, USD 1,512.0 million, and grows fastest at 17.2%, as Japan, China, South Korea, Australia and India expand nuclear medicine capacity and approve therapies. The Middle East contributes USD 252.0 million at 16.0%, Latin America USD 181.4 million at 14.6% and Africa USD 70.6 million at 13.0%. Six regional models sum to the global figure, with country tables in the Excel model.

Who supplies oncology radiopharmaceuticals?

Novartis is the leading company in radioligand therapy, marketing approved lutetium-177 therapies for prostate cancer and neuroendocrine tumours and having built manufacturing and isotope capabilities. Bayer markets radium-223 for prostate cancer. Eli Lilly, AstraZeneca and Bristol Myers Squibb have acquired radiopharmaceutical developers and are advancing pipelines, including actinium-225 based agents. Lantheus supplies diagnostic imaging agents including prostate specific membrane antigen PET tracers, and Telix, Curium, GE HealthCare, Cardinal Health and others supply diagnostic agents, radiopharmacy services and isotopes. Isotope producers, research reactors and specialist companies supply lutetium-177 and actinium-225. The competitive chapter profiles each company’s approved products, pipeline, isotope supply position and manufacturing capacity.

How are radiopharmaceuticals priced?

Average realised price is USD 2,400 per dose in 2025, but this blends two very different categories. Diagnostic doses typically cost from hundreds to a few thousand dollars depending on the tracer, with targeted tracers priced well above conventional agents. Therapeutic doses of radioligand therapy cost tens of thousands of dollars each, and a course usually involves several doses, so a full treatment course is priced similarly to other advanced cancer therapies. Because therapies account for a rapidly growing share of doses, the average price per dose rises over the forecast, which is the reason for the positive price leg. Pricing is shaped by reimbursement negotiations with payers, which vary by country, and by manufacturing and isotope costs. The pricing chapter publishes price bands by product category and region.

How do the scenarios diverge by 2035?

The base case carries 11.0% growth in doses and 3.0% growth in price per dose for a 14.33% revenue CAGR and USD 38,468.3 million in 2035. The supply-constrained scenario, in which isotope production and treatment capacity scale slowly and pipeline agents disappoint, sets the legs at 7.0% and 1.6%, landing near USD 23,300 million. The pipeline-breakthrough scenario, in which multiple new cancer indications are approved, actinium-225 supply scales and therapies move into earlier lines, sets them at 14.0% and 4.4%, carrying the market past USD 58,800 million. Each 1-point change in dose growth moves the 2035 figure by roughly USD 3,370 million.

Which rules and standards apply?

Three layers matter. Drug approval regulation comes first: radiopharmaceuticals must be approved as drugs, with clinical evidence of safety and efficacy, and approvals of new indications drive market expansion. Radiation safety and nuclear regulation is second: production, transport, handling, administration and disposal of radioactive materials are subject to stringent nuclear and radiation protection regulation, including licensing of facilities and staff, which affects the capacity to deliver therapies. Reimbursement and health technology assessment are third: payers assess the value of high cost therapies, and reimbursement decisions determine patient access, particularly in health systems with strict cost effectiveness thresholds. The regulatory chapter maps these requirements by jurisdiction.

What will actinium-225 unlock?

Actinium-225 is widely seen as the key to the next phase of radiopharmaceutical growth, and its supply is the single most important variable for the pipeline. Alpha emitting isotopes such as actinium-225 deliver far more energy over a much shorter distance than beta emitters such as lutetium-177, which means they can kill cancer cells more potently while affecting less surrounding tissue, and they may work in patients whose cancers have become resistant to beta therapies. Many of the most promising pipeline radiopharmaceuticals, including those acquired in the recent wave of deals, use actinium-225. But actinium-225 has historically been available only in very small quantities, and producing it at the scale needed for widespread therapy requires new production routes, including accelerators and reactors using new target materials, that are being developed and built now. If supply scales on schedule, alpha therapies could become a large part of the market in the 2030s; if it lags, pipeline agents will be constrained regardless of clinical results. The model treats alpha emitters as a growing category whose pace depends on supply, with the pipeline breakthrough scenario reflecting successful scale up.

Douglas Exclusive: the isotope supply and capacity ledger

This report ledgers, by isotope and producer, current and planned production capacity for lutetium-177, actinium-225 and diagnostic isotopes, reactor and accelerator status, dose manufacturing capacity, and projected demand from approved and pipeline therapies, identifying supply gaps by year and converting clinical demand into deliverable doses and revenue by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from doses: cancer imaging procedure volumes by tracer and region, patients treated with approved radioligand therapies and projected uptake of pipeline agents by indication, doses per course, isotope supply constraints, and realised prices from company disclosures and reimbursement data, with non oncology nuclear medicine, imaging equipment, external beam radiotherapy and brachytherapy excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.